Showing results (171-180 of 782) with videos related to

Sort By:
Pageof 79
The Lancet. HIV|December 7, 2023
HIV-1 reservoir size after neonatal antiretroviral therapy and the potential to evaluate antiretroviral-therapy-free remission (IMPAACT P1115): a phase 1/2 proof-of-concept studyDeborah Persaud, Yvonne Bryson, Bryan S Nelson, et al.
The Lancet. HIV|December 23, 2023
Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trialsChloe Orkin, Jean-Michel Molina, Pedro Cahn, et al.
The Lancet. HIV|January 15, 2024
Changes in incidence of hepatitis C virus reinfection and access to direct-acting antiviral therapies in people with HIV from six countries, 2010-19: an analysis of data from a consortium of prospective cohort studiesRachel Sacks-Davis, Daniela K van Santen, Anders Boyd, et al.
The Lancet. HIV|September 23, 2024
Health impact, budget impact, and price threshold for cost-effectiveness of lenacapavir for HIV pre-exposure prophylaxis in eastern and southern Africa: a modelling analysisLinxuan Wu, David Kaftan, Rachel Wittenauer, et al.
The Lancet. HIV|October 21, 2023
Skin cancer risk in people living with HIV: a call for actionJacob P Reinhart, Kieron S Leslie
The Lancet. HIV|July 14, 2023
Efficacy and safety of the novel capsid inhibitor lenacapavir to treat multidrug-resistant HIV: week 52 results of a phase 2/3 trialOnyema Ogbuagu, Sorana Segal-Maurer, Winai Ratanasuwan, et al.
The Lancet. HIV|August 4, 2023
A multilevel health system intervention for virological suppression in adolescents and young adults living with HIV in rural Kenya and Uganda (SEARCH-Youth): a cluster randomised trialTheodore Ruel, Florence Mwangwa, Laura B Balzer, et al.
The Lancet. HIV|August 11, 2023
Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trialMoti N Ramgopal, Antonella Castagna, Charles Cazanave, et al.
The Lancet. HIV|June 3, 2023
The effects of cash transfer programmes on HIV/AIDS prevention and care outcomes: a systematic review and meta-analysis of intervention studiesNathalia Sernizon Guimarães, Laio Magno, Adelzon Assis de Paula, et al.
The Lancet. HIV|September 16, 2023
Checklist for studies of HIV drug resistance prevalence or incidence: rationale and recommended useLawrence Mbuagbaw, Cristian Garcia, Bluma Brenner, et al.
Pageof 79